A controlled study on the preventive effect of ketotifen, an antiallergic agent, on methacholine-induced bronchoconstriction in asthmatics.
We studied the preventive effect of ketotifen, an oral drug with antianaphylactic and antihistaminic properties on methacholine-induced bronchoconstriction in controlled cross-over experiments in twenty-six adult patients with extrinsic asthma. Both a single dose of 1 mg ketotifen and 4 weeks treatment of ketotifen, 1 mg twice daily, failed to reduce the methacholine-induced drop in peak expiratory flow. The spirometric findings remained unchanged during ketotifen treatment. There was no difference between treatments with ketotifen and placebo with regard to the patients assessment of the severity of asthma or airway sensitivity to tobacco smoke, fumes or dusts, or exercise. The results suggest that treatment during 4 weeks with ketotifen does not reduce unspecific broncial hyperreactivity in patients with extrinsic asthma.
D000293:Adolescent; D000328:Adult; D000707:Anaphylaxis / Q000188:drug therapy; D001249:Asthma / Q000188:drug therapy*; D001986:Bronchial Spasm / Q000188:drug therapy*; D004305:Dose-Response Relationship, Drug; D004311:Double-Blind Method; D006634:Histamine H1 Antagonists / Q000009:adverse effects / Q000627:therapeutic use*; D006801:Humans; D008688:Methacholine Compounds / Q000494:pharmacology*; D008875:Middle Aged; D010880:Piperidines / Q000627:therapeutic use*; D013147:Spirometry; D013876:Thiophenes / Q000627:therapeutic use*
D006634:Histamine H1 Antagonists; D008688:Methacholine Compounds; D010880:Piperidines; D013876:Thiophenes